MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.5% - Time to Buy?

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) shot up 0.5% during trading on Tuesday . The company traded as high as $1.89 and last traded at $1.84. 126,674 shares were traded during mid-day trading, a decline of 45% from the average session volume of 229,457 shares. The stock had previously closed at $1.83.

MAIA Biotechnology Stock Down 4.0%

The firm has a market cap of $58.50 million, a price-to-earnings ratio of -2.44 and a beta of 0.03. The company's fifty day moving average is $1.82 and its 200 day moving average is $1.89.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Stan Smith bought 33,333 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were acquired at an average cost of $1.50 per share, with a total value of $49,999.50. Following the acquisition, the director owned 1,305,059 shares of the company's stock, valued at $1,957,588.50. The trade was a 2.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 32.32% of the company's stock.

Institutional Trading of MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned approximately 0.15% of MAIA Biotechnology as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.